Pediapharm Inc. announced that it has entered into definitive agreements to acquire two speciality pharmaceutical companies and also intends to complete a private placement offering for up to CAD 60 million. Upon completion of the Transactions, the board of directors of Pediapharm will be reconstituted to consist of seven directors, comprised of four existing directors (Pierre Lapalme, Sylvain Chretien, Michael Mueller and Benoit Gravel) and three new directors (Ken d'Entremont, Stephen Nelson and Peter van der Velden).